Mitigating the cardiovascular and renal effects of NSAIDs

Pain Medicine (United States)

Volumn 14, Issue SUPPL1, 2013, Pages

  Curiel, Rodolfo V ^a   Katz, James D ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Cardiovascular Risk; Complications; Cyclo Oxygenase 1; Cyclo Oxygenase 2; Drug Therapy; Epidemiology; Nonsteroidal Anti Inflammatory Drugs; Prostacyclins; Renal Insufficiency; Thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; THROMBOXANE A2;

ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART PROTECTION; HUMAN; MEDICAL DECISION MAKING; NEPHROTOXICITY; NONHUMAN; PRACTICE GUIDELINE; REDUCTION; THROMBOCYTOPOIESIS;

CARDIOVASCULAR RISK; COMPLICATIONS; CYCLO-OXYGENASE-1; CYCLO-OXYGENASE-2; DRUG THERAPY; EPIDEMIOLOGY; NONSTEROIDAL ANTI-INFLAMMATORY DRUGS; PROSTACYCLINS; RENAL INSUFFICIENCY; THROMBOXANE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; KIDNEY DISEASES;

EID: 84890889182     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12275     Document Type: Review

References (51)

1. Zhang W, Doherty M, Leeb BF, etal. EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies including therapeutics (ESCISIT). Ann Rheum Dis 2007;66(3):377-388.
2. Zhang W, Moskowitz RW, Nuki G, etal. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cart 2008;16(2):137-162.
3. Lawrence RC, Helmick CG, Arnett FC, etal. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1984;41:578-799.
4. Roth SH, Anderson S. The NSAID dilemma: Managing osteoarthritis in high-risk patients. Phys Sportsmed 2011;39(3):62-74.
5. Tsang A, Von Korff M, Lee S, etal. Common chronic pain conditions in developed and developing countries; gender and age differences and comorbidity with depression-anxiety disorders. J Pain 2008;9(10):883-891.
6. Centers for Disease Control and Prevention Public Health Service U.S. Department of Health and Human Services. Osteoarthritis and you: Patient information from the CDC. J Pain Palliat Care Pharmacother 2010;24(4):430-431.
7. FDA. Safety alerts for human medical products. COX-2 selective and non-selective non-steroidal anti-inflammatory drugs NSAIDs. 2005. Available at: http://www.fda.gov/Drugs/Drugsafety/ (accessed November 2013).
8. Lanas A, Garcia-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular risk history in patients with diagnosis of osteoarthritis. BMC Med 2011;9:38-45.
9. Whelton A, Maurath CJ, Verbug KM, etal. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000;7:159-175.
10. Praveen Rao PN, Knaus E. Evolution of nonsteroidal anti-inflammatory drugs: Cyclooxygenase inhibition and beyond. J Pharm Pharm Sci 2008;11(2):81s-110s.
11. Grosser T, Fries S, FitzGerald GA. Biological basis for cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15.
12. Fitzgerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984;310:1065-1068.
13. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-1711.
14. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005;112:759-770.
15. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001;110:33S-42S.
16. Komhoff M, Grone HJ, Klein T, etal. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implications for renal function. Am J Physiol Renal Physiol 1997;272:F460-468.
17. Rios A, Vargas-Robles H, Gamez-Mendez AM, Escalante B. Cyclooxygenase-2 and kidney failure. Prostaglandins Other Lipid Mediat 2012;98(3-4):86-90.
18. Green T, Gonzalez AA, Mitchell KD, Navar LG. The complex interplay between cyclooxygenase-2 and angiotensin II in regulating kidney function. Curr Opin Nephrol Hypertens 2012;21:7-14.
19. Gonzalez AA, Cespedes C, Villanueva S, etal. E-prostanoid-1 receptor regulates renal medullary alphaENaC in rats infused with angiotensin II. Biochem Biophys Res Commun 2009;389:372-377.
20. Kim SM, Chen L, Mizel D, etal. Low plasma renin and reduced renin secretory responses to acute stimuli in conscious COX-2-deficient mice. Am J Physiol Renal Physiol 2007;292:F415-422.
21. Lewington S, Clarke R, Qizilbash N, etal. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
22. Furberg CD. The COX-2 inhibitors: An update. Am Heart J 2006;152:197-199.
23. Barkin LB, Buvanendran A. Focus on the COX-1 and COX-2 agents: Renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. Am J Ther 2004;11(2):124-129.
24. Barkin RL, Barkin D. Pharmacologic management of acute and chronic pain: Focus on drug interactions and patient specific pharmacotherapeutic selection. South Med J 2001;94:755-770.
25. Barkin RL, Beckerman M, Blum SL, etal. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 2010;27:775-789.
26. Brater C, Harris C, Redfern JS. Renal effects of COX2 selective inhibitors. Am J Nephrol 2001;21:1-15.
27. Barkin RL, Barkin DS. Pharmacotherapeutic challenges in the elderly: Polypharmacy, drug interactions, compliance and side-effects/adverse-effects predictions. Anesth Today 1998;9:12-19.
28. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008;52(20):1628-1636.
29. 2 production in healthy subjects. Thromb Res 1980;17:317-327.
30. Patrignani P, Panara MR, Greco A, etal. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994;271:1705-1712.
31. Patrignani P, Panara MR, Sciulli MG, etal. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 1997;48:623-631.
32. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186.
33. Van Hecken A, Schwartz JI, Depre M, etal. Comparative inhibitory activity of rofecoxib, meloxican, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-1120.
34. Patrono C, Ciabattoni G, Patrignani P, etal. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177-1184.
35. Di Minno G, Silver MJ, Murphy S. Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 1983;61:1081-1085.
36. Komhoff M, Grone HJ, Klein T, etal. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implications for renal function. Am J Physiol Renal Physiol 1997;272:F460-468.
37. Day RO, Francis H, Vial J, Geisslinger G, Williams KM. Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. J Rheumatol 1995;22(12):2295-2303.
38. Nahata MC, Durrell DE, Powell DA, Gupta N. Pharmacokinetics of ibuprofen in febrile children. Eur J Clin Pharmacol 1991;40(4):427-428.
39. Catella-Lawson F, Reilly MP, Kapor SC, etal. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817.
40. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361(9357):573-574.
41. Gengo FM, Rubin L, Robson M, etal. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: Clinical consequences in stroke prophylaxis. J Clin Pharmacol 2008;48(1):117-122.
42. Renda G, Tacconelli S, Capone ML, etal. Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006;80(3):264-274.
43. Kearney PM, Baigent C, Godwin J, etal. Do selective cyclooxygenase-2 inhibitors and traditional anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ 2006;332:1302-1308.
44. Mukherjee D. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic and anti-inflammatory drugs? Arguments in favor. Thromb Haemost 2006;96:407-412.
45. Timmers L, Sluijter JPG, Verlaan CWJ, etal. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 2007;115:288-291.
46. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, etal. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: A nationwide cohort study. Circulation 2011;123(20):2226-2235.
47. Antman EM, Bennett JS, Daugherty A, etal. Use of nonsteroidal anti-inflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation 2007;115(12):1634-1642.
48. Kienzler J, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol New Drugs 2010;50:50-61.
49. Gislason GH, Jacobsen S, Rasmussen JN, etal. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113:2906-2913.
50. Kearney D, Byrne A, Crean P, etal. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: No additional effect of a selective cyclooxygenase-2 inhibitor. J Am Coll Cardiol 2004;43(4):526-531.
51. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A 1996;93:10417-10422.